Summary & Overview
HCPCS J1095: Intraocular Injection of Dexamethasone 9% (1 mcg)
HCPCS Level II code J1095 represents an intraocular injection of dexamethasone 9 percent, 1 microgram, used to deliver corticosteroid therapy directly into the eye. This code is relevant nationally for ophthalmology practices, ambulatory surgical centers, and hospital outpatient departments that provide targeted intraocular anti-inflammatory treatment. It matters for billing, coverage determinations, and coding accuracy given the specialized route of administration and medication concentration.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code denotes, typical sites of service, and the clinical context for intraocular corticosteroid administration. The publication outlines benchmarks and coverage considerations commonly addressed by major payers, highlights potential policy updates affecting injectable ophthalmologic therapies, and situates the code within clinical practice for retinal and intraocular inflammatory conditions.
This summary helps coding and billing staff, compliance officers, and clinical leaders understand where HCPCS Level II code J1095 fits in scheduling, revenue cycle workflows, and payer interactions, and what topics to expect in the full publication.
Billing Code Overview
HCPCS Level II code J1095 describes an injection of dexamethasone 9 percent, intraocular, 1 microgram. This code represents an intraocular pharmacologic therapeutic procedure intended to deliver a corticosteroid directly into the eye for local anti-inflammatory effect.
-
Service type: Intraocular injection (intravitreal/intraocular pharmacologic administration)
-
Typical site of service: Ambulatory ophthalmology clinic, ambulatory surgical center, or hospital outpatient setting where intraocular injections are performed
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of diabetic macular edema presents to a retinal specialist for intravitreal therapy. After ophthalmic examination and optical coherence tomography confirming persistent central macular thickening, the provider selects an intraocular corticosteroid formulation of dexamethasone to reduce inflammation and macular edema. The patient is prepped in a procedure room or ambulatory surgical center; topical anesthesia and antisepsis with povidone-iodine are applied. The clinician performs an intravitreal injection of J1095 (injection, dexamethasone 9 percent, intraocular, 1 microgram) into the vitreous cavity using sterile technique. Post-injection, the patient is observed for intraocular pressure elevation and endophthalmitis signs for a brief monitoring period, instructed on post-procedure precautions, and scheduled for follow-up intraocular pressure checks and retinal imaging to assess treatment response and plan further injections if indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard procedural service | Use when no modifier applies and full service rendered. |
22 |